Depletion of TIGIT+ populations including Tregs has been reported in tumor samples obtained from patients treated with Fc-optimized TIGIT antibodies and was considered important for the therapeutic effects of the antibodies [79,80]. The gene discussed is TIGIT; the disease is neoplasm.